| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790048 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
Patients with early stage tumors that present concomitant loss of both PBRM1 and BAP1 demonstrated worse survival rates and represent a relevant risk group for tumor recurrence and death.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Walter Henriques M.D., Ph.D., Isabela Werneck Ph.D., Aline Fusco M.D., Ph.D., Stephania M. M.D., Luciana M.D., Ph.D., Diego Abreu M.D., Deusdedit Vieira M.D., George Jabboure Ph.D., M.D., Gustavo Cardoso M.D., Ph.D., Stenio de M.D., Ph.D.,